Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + Rilvegostomig
Phase 2Recruiting 3 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer
Trial Timeline
Jun 3, 2020 → Jun 1, 2027
NCT ID
NCT04379596About Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + Rilvegostomig
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + Rilvegostomig is a phase 2 stage product being developed by Daiichi Sankyo for Gastric Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04379596. Target conditions include Gastric Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04379596 | Phase 2 | Recruiting |
Competing Products
20 competing products in Gastric Cancer